报价延迟最少15分钟:2025/09/14 16:50 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
39.42 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.28/0.93
|
|
企业价值
1.69B
|
| 资产负债 |
|
每股账面净值
1.34
|
| 现金流量 |
|
现金流量率
0.00
|
| 损益表 |
|
收益
199.61M
|
|
每股收益
2.78
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/14 16:50 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sightby making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business. |
